FGFR2 Polyklonaler Antikörper
FGFR2 Polyklonal Antikörper für IF, IHC, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human und mehr (1)
Anwendung
IHC, IF, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 13042-1-AP
Synonyme
Galerie der Validierungsdaten
Geprüfte Anwendungen
| Erfolgreiche Detektion in IHC | humanes Mammakarzinomgewebe, humanes Prostatakarzinomgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
| Erfolgreiche Detektion in IF | HepG2-Zellen |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Immunhistochemie (IHC) | IHC : 1:50-1:500 |
| Immunfluoreszenz (IF) | IF : 1:10-1:100 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| IHC | See 1 publications below |
| IF | See 1 publications below |
Produktinformation
13042-1-AP bindet in IHC, IF, ELISA FGFR2 und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| In Publikationen genannte Reaktivität | human, Maus |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | FGFR2 fusion protein Ag3701 |
| Vollständiger Name | fibroblast growth factor receptor 2 |
| Berechnetes Molekulargewicht | 709 aa, 79 kDa |
| Beobachtetes Molekulargewicht | |
| GenBank-Zugangsnummer | BC039243 |
| Gene symbol | FGFR2 |
| Gene ID (NCBI) | 2263 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3. |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
FGFR2 (Fibroblast growth factor receptor 2) is a tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis. Ligand binding leads to the activation of several signaling pathway, such as RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP Kinase signaling pathway, as well as the AKT1 signaling pathway. Mutations in the gene of FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. This polyclonal antibody raised against 358-704aa of human FGFR2 can cross react with other members of the FGFR family.
Protokolle
| Produktspezifische Protokolle | |
|---|---|
| IHC protocol for FGFR2 antibody 13042-1-AP | Protokoll herunterladen |
| IF protocol for FGFR2 antibody 13042-1-AP | Protokoll herunterladen |
| Standard-Protokolle | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
Am J Cancer Res miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2. | ||
Nephron The Effects of M1/M2 Macrophages on the mRNA Expression Profile of Diabetic Glomerular Endothelial Cells. | ||
Anim Biotechnol MiR-125b regulates the differentiation of hair follicles in Fine-wool Sheep and Cashmere goats by targeting MXD4 and FGFR2. | ||
Life (Basel) MPP7 as a Novel Biomarker of Esophageal Cancer: MPP7 Knockdown Inhibits Esophageal Cancer Cell Migration and Invasion | ||
Tissue Eng Part A The UC-MSCbFGF/scaffold system accelerates the healing of the uterine full-thickness injury |
Rezensionen
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
FH Kus (Verified Customer) (12-08-2022) | Works good WB but could see working for Immunofluorescence.
|
FH K (Verified Customer) (02-02-2022) | This Ab works great for immunofluorescence and IHC at 1:200 dilution but this Ab did not work well for western blotting.
|
